Category Archives: Life Extension

It was already clear that the Red Sox and third baseman Rafael Devers were very far off from each other in extension talks during spring training. Now, some details have emerged on how just much of a difference there was between the sides.

The Red Sox and Devers were more than $100 million apart in talks, according to Jon Heyman of the New York Post. That jibes with reporting from ESPNs Jeff Passan, who told WEEIs The Greg Hill Show on Wednesday that the Red Sox are over $200 million and that Rafael Devers wants more than $300 million in recent discussions.

The Red Sox are said to have offered the excellent young slugger Devers nothing like what he was seeking in terms of length or dollars, Heyman wrote. Word is, Devers was looking for an ultra-long deal that would have made him a Red Sox for life, while the club was thinking more like a contract for much less length a kind of half-life deal. The teams exact offer isnt known, but suffice it to say, they were surely more than $100 million apart.

Devers, 25, is set to become a free agent after the 2023 season. He has said that he doesnt want to negotiate during the regular season, meaning the sides will have to wait until next winter to hammer out a potential long-term deal.

This thing is playing out, guys, in a very, very similar fashion to Mookie Betts, Passan told WEEI, referencing how the Red Sox failed to come to terms with Betts on an extension before trading him to the Dodgers in Feb. 2020.

The Red Sox and Devers had discussions toward the end of spring training but those broke off once it was clear the sides werent close to an agreement. Boston also failed to lock up shortstop Xander Bogaerts, who was reportedly offered a below-market, four-year, $90 million extension (thats really a 1-year, $30 million add-on to the three years left on his contract) in an effort from preventing him to opt out this fall.

Appearing on MassLives Fenway Rundown podcast Tuesday, chief baseball officer Chaim Bloom said the club still wants to sign both Bogaerts and Devers despite talks breaking down during camp.

I dont love getting into too much detail on these types of things unless we actually do get to a deal. I think its really up to the players, how much they want to say, Bloom said. Basically, both those guys have talked about it to varying degrees. We would love to have both guys here for a long time. We want to do it in a way that makes sense for them and makes sense for us. Obviously, this spring, we didnt find that path but we want to have them here and hopefully we will find it.

Related links:

Boston Red Sox offered Xander Bogaerts 4-year, $90 million extension; a slap in the face, one of his friends says (report)

Trevor Story gets first Boston Red Sox RBI after missing three games with food poisoning, convincing Alex Cora he was good to go

How Chaim Bloom has blocked out the noise since joining Boston Red Sox, despite occasionally searching his name on Twitter

The rest is here:

Boston Red Sox, Rafael Devers more than $100M apart in extension talks: Its playing out in a very similar f - MassLive.com

Artist's impression of the Dreadnought-class submarine. Credit: UK Ministry of Defence

According to the US Stockpile Stewardship and Management Plan released last month, the development of the United States first new nuclear warhead since the Cold War appears to be proceeding. Collective sighs of relief are emanating from Washington and London. But they may be louder in the United Kingdom.

Last October, despite resistance from Democrats, the US Senate Armed Services Committee authorized $134 million of 2022 funding for the W93 submarine-launched ballistic missile warhead and the Mark 7 aeroshell re-entry body for the Trident II D5 missiles that will carry it. The Energy Department has been vague in describing the W93, referencing it as a new program of record rather than a new warhead. The new stockpile plan lays out a more detailed and accelerated timeline for the W93, but remains ambiguous in regard to details, saying the program offers the Navy a modernized warhead capability that incorporate(s) modern technologies to address future threats. The warhead apparently is intended to ensure continuity, replacing older W76 and W88 warheads as they are phased out of service.

The United States need for the W93 is not as urgent as the timeline suggests. Both existing warheads have recently undergone costly modernization and life-extension programs and seem likely to remain in deployment for many years, and perhaps decades.

The programs urgency seems attributable to the United Kingdoms nuclear modernization efforts. The Royal Navy is undergoing a sweeping renewal of its nuclear forces, including the construction of four new Dreadnought-class submarines. Part of the long process reaffirmed in an update to Parliament late last year involves the delivery of a new British warhead in parallel with the US W93/Mk7 warhead program.

It ought to come as no surprise that Washington and London are cooperating on the new warhead program: The two countries use identical Trident II D5 missiles from a common pool located in Kings Bay, Georgia, which makes warhead compatibility essential. But the partnership is raising questions about Britains sovereignty and who is footing the bill for the W93.

Unfounded urgency. Over the course of 25 years of studies, engineering, and production, the W93 program may cost up to $14 billion, with production of the first warheads expected between 2034 and 2036. The case for embarking on the program was made in the latter days of the Trump administration; its urgency remains open to question. The Navy has spent large sums modernizing the submarine-launched ballistic missile warheads the Navy now deploys on its 14 Ohio-class submarines, the W76 and W88. One prevailing reason for the new program is the Navys numerical reliance on the older, lower-yield W76-1 and W76-2 warheads, at 90 kilotons and 8 kilotons respectively, which outnumber the 455-kiloton thermonuclear W88 by almost five to one in the arsenal. An unclassified white paper from 2020 suggests the W93 would likely offer a variable- or at least higher-yield alternative, diversifying the Navys warfighting options by allowing it to hold all targets in current plans at risk.

Obvious overlap between the US and British programs ends with the Trident missiles. But circumstances around the W93 program suggest more than meets the eye. London needs a new warhead more than Washington does; not only does the United Kingdom rely solely on its nuclear submarines for its deterrent, lacking intercontinental ballistic missiles and bombers like those of the United States, but it has also never deployed the W88relying exclusively on the older W76, or Holbrook warheads, as they are known.

Very significant implications. The British government has insisted on its countrys nuclear sovereignty since it first developed its deterrent, but poor management and expensive delays have damaged this claim in recent years, while previous indigenous programs have failed. In a 2020 House of Commons Defense Briefing, then-Permanent Secretary of the Ministry of Defence Sir Stephen Lovegrove admitted that British funds for a warhead replacement would run out in four years, adding that uncertainty in Washington about the program would have very significant implications for the United Kingdom. Allegations that the W93 was more for the British than the American deterrent were not helped when it emerged that British Defence Secretary Ben Wallace had directly lobbied members of Congress to support its funding in 2020.

US officials have not helped either, reiterating in the recent stockpile plan that the W93 program was also vital for continuing our longstanding cooperation with the United Kingdom, whose nuclear deterrent is critical to US national security. Warhead programs are costly and take decades of research and development, but there are real concerns the W93 is not an urgent need for the Navy. Chair of the House Armed Services Committee Rep. Adam Smith suggested as much, noting that the program may arguably be a little bit ahead of need and that the UK is pushing a lot of that. The question for lawmakers is therefore the inherent value of the British deterrent to US national security, especially for a program the United States does not need and for which it appears to be footing much of the bill.

The war in Ukraine has seemingly reaffirmed the Biden administrations commitment to its NATO allies, with the recent Nuclear Posture Review summary also ruling out a no-first-use policy long opposed by many allies in Europe. In this case, however, even the long-held nuclear cooperation between Washington and London does not justify the development of the first new nuclear weapon in decades.

The cost of the W93 program and the urgency with which it is being pursued have not yet been justified. The United States should not rush to design and build a symbolic new warhead for the arsenal of an ally, even one as close as Britain, when Congress has so far failed to build a case for it on much more than British interest alone.

As for London, the Ministry of Defence has built an equally unconvincing case and, perhaps worse for its security, one that exposes a deep reliance on an ally for its supposedly independent deterrent. The war in Ukraine and heightened tensions with Russia must not dictate unnecessary modernization spending.

Read this article:

America's new multibillion-dollar nuclear warhead is a great deal for the British - Bulletin of the Atomic Scientists

Northampton, MA --News Direct-- Entergy Corporation

Volunteering and giving are at the heart of our mission to power life, and our employees embody this commitment every day. In honor of National Volunteer Month a monthlong celebration recognizing volunteers and encouraging continued volunteerism in April we are shining a light on the selfless spirit of six employees who dedicate their time to give back in Arkansas, Louisiana, Mississippi, New Orleans and Texas.

Arkansas

Amy Sotomayer, ALARA specialists at Arkansas Nuclear One, is committed to volunteerism because she believes that it is not always where someone is from or where they have been it is about where they are going. She is driven to volunteer in her community because she wants to help create positive change for the future. She enjoys volunteering with the local school districts youth to help develop their leadership skills by hosting job fairs, teaching life skills and engaging in their academic success.

I am proud to be a part of a company that provides resources and dedicates their time to support the causes that mean so much to us. Whether it is working with students or engaging with the Special Olympics, Entergy does everything they can to help us be successful in giving back to our community.

Louisiana

Laura Beauchamp, director of resource planning and market operations in Louisiana, is committed to volunteerism because she enjoys building relationships with her community, neighbors and other employees at Entergy. One of her favorite volunteer events is working with the New Orleans Mission to serve Thanksgiving dinner to local members and those in need.

I am always encouraging my team and the teams around me to give back because that is how we ensure that we are all are providing a bright future for the next generation.

Mississippi

David Notbohm, director of continuous improvement in Mississippi, volunteers with Scouts BSA troops and the Sea Scout program to help members build life skills and confidence in the areas of science, technology, engineering, math and the outdoors.

Story continues

Ive been given so many opportunities to learn and gain skills in life and with my career. Working with youth allows me to pay it forward so they can receive the opportunities that I have experienced.

New Orleans

Abdul Yanusah, line superintendent in New Orleans, is committed to volunteerism because it gives him the opportunity to get out and meet neighbors and the people he helps provide power to. One of his favorite volunteer events includes partnering with Goodwill Industries and Central City Fellowship to pass out household essentials, such as cleaning supplies, hygiene products, diapers and meals to those in need.

As a New Orleans native, it is important for me to give back to an area where I grew up because I want to see us all thrive. I am grateful for the opportunity to power life in our neighbors homes and the community.

Texas

Brenda Davis, administrative assistant in Texas dedicates her time to volunteer with the Southeast Texas Food Bank, Field of Plenty, Orange County Texas Agri Life Extension and the Vidor High School Band Boosters. She has played a significant role in getting her co-workers involved in feeding those in need, teaching local youth kitchen safety and supporting the needs of the high school band.

"I could be the difference in whether someone is offered a service, provided food, mentored or shown a good role model. We can do so much more when we all work together, pulling in the same direction."

Corporate

Kenyon Webber, senior engineer in transmission, is committed to volunteering because she sees the positive impact that we have on communities when we all work together. She enjoys volunteering with STEM NOLA/STEM Global Action, Girl Scouts, the STEM Library Lab and STEM Goes Red at the American Heart Association.

I am passionate about showing students the wonders of STEM, careers in STEM and how to think critically. As a hometown champion, I want to relate to my community, meet them where they are and be a good neighbor.

We strive to contribute to a society that is healthy, educated, environmentally safe and productive. By showing the same enthusiasm for volunteerism as we do for providing customers with safe, reliable and affordable energy, Entergy employees demonstrate why they are known as the best in the industry.

During another year of uncertainty, employees and retirees remained dedicated to serving our communities by logging more than 100,000 volunteer hours in 2021, resulting in a $3.3 million economic impact to local economies. Approximately 1,800 of the total hours were dedicated to pro bono efforts, resulting in $477,000 of in-kind legal services.

Last year, our commitment to volunteerism helped earn the company recognition from Points of Light as one of the 50 most community-minded companies in the country for the sixth consecutive year. Entergy was also named to the 100 Best Corporate Citizens List by 3BL Media

View videos of Entergy volunteers celebrating National Volunteer Month.

View additional multimedia and more ESG storytelling from Entergy Corporation on 3blmedia.com

View source version on newsdirect.com: https://newsdirect.com/news/celebrating-entergy-employees-for-their-dedication-to-our-communities-282637299

See the original post here:

Celebrating Entergy Employees for Their Dedication to Our Communities - Yahoo Finance

The 140-member crew of U.S. Coast Guard Cutter Polar Star (WAGB 10) returned to the United States and entered dry dock Friday after completing a 147-day deployment in support of the U.S. Antarctic Program and national interests in Antarctica and the Southern Hemisphere.

The Polar Stars crew departed their Seattle homeport on Nov. 13, 2021 for the cutters 25th Operation Deep Freeze deployment and traveled 24,300 nautical miles to Antarctica and back.

This year marks the 66th iteration of Operation Deep Freeze, an annual joint military service mission in support of the National Science Foundation, the lead agency for the United States Antarctic Program. Since 1955, the U.S. Department of Defense and the Coast Guard have provided air and maritime support across and around the Antarctic continent.

The cutter made several international port calls including stops in Wellington and Lyttelton, New Zealand, and Hobart, Tasmania, Australia. Polar Stars crew hosted the U.S. Ambassador to New Zealand and members of the Royal New Zealand Navy while in New Zealand.

While in Antarctica, Polar Star transited through more than 450 miles of pack ice and broke a 37-mile channel through seven-foot thick fast ice to McMurdo Station to allow the safe transit and offload of supply vessels Ocean Giant and Maersk Peary.

Polar Star also partnered with the Royal New Zealand Navy to escort the ice-capable logistics ship HMNZS Aotearoa for its first trip to McMurdo Station.

Polar Star transited to the Bay of Whales Feb. 17, setting a record for the furthest south any vessel has navigated, reaching 78 degrees 44 minutes 1.32 seconds south latitude, keeping about 500 yards from the ever shifting Ross Ice Shelf. The cutter also surveyed 396 nautical miles of the ice shelf for future navigational use.

Polar Star spent a total of 65 days in Antarctica, making it the longest Operation Deep Freeze deployment completed by a Coast Guard polar icebreaker in 18 years.

After completing operations in Antarctica, Polar Star moored in Hobart and hosted the Governor of Tasmania, Barbara Baker, and U.S. Consul General Kathleen Lively, along with several other government and military officials that are dedicated to supporting scientific efforts in Antarctica.

I am so proud of this crew and their accomplishments, said Capt. William Woityra, commanding officer of the Polar Star. They overcame constant challenges to complete the mission and set records along the way. They epitomize the values on the Antarctica Service Medal: courage, sacrifice, and devotion. I can think of no better team to lead future expeditions and new icebreakers as the Coast Guard invests in Polar Security Cutters.

Polar Star did not return to its homeport of Seattle, instead the crew proceeded directly to dry dock in Vallejo, California, to immediately start work on the second phase of a five-year, $75 million Service Life Extension Program. The Coast Guard will replace antiquated technology to ensure the longevity of the nations only operational heavy icebreaker while in dry dock this year, supporting the Coast Guards enduring commitment to Antarctic operations.

The Coast Guard has been the sole provider of the nations polar-icebreaking capability since 1965. Commissioned in 1976, the Polar Star is the United States only operational heavy icebreaker. The Coast Guard is increasing its icebreaking fleet with construction of three new Polar Security Cutters (PSC) to ensure persistent national presence and reliable access to the Polar Regions. Coast Guard Commandant Adm. Karl L. Schultz revealed the name of the first PSC Coast Guard Cutter Polar Sentinel during his 2022 State of the Coast Guard Address.

Read more at USCG

See the original post here:

Nation's Sole Heavy Icebreaker Returns to the US After a 147-Day Antarctic Deployment - HS Today - HSToday

The new report titled Wellness Supplements Market Report helps clients to gain a better understanding of making intelligent and informed decisions about the Wellness Supplements industry. The report includes a detailed list of key players dominating the Wellness Supplements market by providing market feasible data sources and then further analysis. The comprehensive and quality reports are prepared with the goal of empowering clients with thorough knowledge of market capacity in a real-time marketplace.

Get a Sample Copy of the Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-wellness-supplements-market&KA

Wellness SupplementsMarket Insight:

Wellness supplements market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 386.29 billion by 2027 growing at a CAGR of 6.45% in the above-mentioned forecast period. The growing awareness towards healthy lifestyles among the people globally will help in driving the growth of the wellness supplements market.

The competitive landscape of Wellness Supplements market research includes extensive analysis of regions including North America, Europe, Asia Pacific, Middle East & Africa, Latin America, which are projected to capture the essence of the market in the broadest category. This list includes key players dominating the industry based on overall system capacity, environmental contribution, appropriate channels and geographic proximity through a system of primary and secondary research methodologies, which adds to our internal analytical model. Monetization and generalized market share for the Wellness Supplements market are also displayed via charts, graphs, and tables.

Some of the key players operating in the global Wellness Supplements market include:

Life Extension, OPTAVIA LLC, Beachbody LLC, Natures Sunshine Products, Inc, Organo Gold., Thrive Life, LLC, Phytoscience Trvo, Oriflame Cosmetics AG, Melaleuca Inc, Shaklee Corporation, Arbonne International, LLC., Forever Living.com, L.L.C, Juice Plus+, Herbalife International of America, Inc, and Isagenix Worldwide LLC, Nikken Inc., Wellness Resources, Inc., The Daily Wellness Company, Otsuka Holdings Co. Ltd, Glanbia plc, Nestle, Nuskin, USANA Health Sciences, Inc.,

Reports key features:

Detailed Wellness Supplements Market Overview

Changing industry market dynamics

Comprehensive analysis of market segmentation

Market size in terms of volume and value, historical, present and forecast

Recent industry trends and developments

Wellness Supplements Market Competing Countries

Key Player Strategies and Products

The Wellness Supplements report also contains primary and secondary information pertaining to the global market in terms of global status, market size, growth forecasts, trends, segments and detailed forecasts. In addition, key collaborations, mergers and acquisitions, key market trends and business policies are evaluated in the report.

Know More About this Study @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-wellness-supplements-market&KA

Key questions The report answers:

What will the market size and growth rate be in the Forecasted Period?

What are the main drivers of the global Wellness Supplements market?

What are the key market trends influencing the global market growth Wellness Supplements?

What are the market growth challenges?

Who are the major global market vendors for Wellness Supplements?

Global Wellness Supplements Markets Markets What are the market industry opportunities and challenges for vendors?

What are the key outcomes of the global Wellness Supplements market five-point analysis?

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @https://www.databridgemarketresearch.com/toc/?dbmr=global-wellness-supplements-market&KA

Wellness Supplements market report includes market forecasts related to future global estimates, share, business forecasts, current manufacturers scenario, competitive landscape and forecast and other important factors. With an in-depth analysis of developments affecting the business, this report has included detailed information about the business. The survey data was done taking into account the current top players and their next contenders.

Contact us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See more here:

Wellness Supplements Market With Current Scenario and Industry Forecast to 2028 Political Beef - Political Beef

Versatility has always been the name of the hair game. Be it clip-ins, a fall, or extensions, women like to know that they have options. Lets be clear, hair is a fashion accessory and has been for centuries, and while hairstyles and pieces have evolved over the years, from the towering powdered coiffures of the 18th century to today's thick, luxurious yet natural look, the desire for body, length, and versatility has remained the same.

Most hairstylists and consumers still embrace the classic and traditional ways of achieving a long mane with bonding and sew-ins, but with technology constantly expanding in the world of hair, you now have different options to achieve the same results, says Tish Celestine, celebrity hairstylist and owner of LaBelle Boutique. Tape-ins can make life easier in some instances, and are popular among hair enthusiasts.

Sophia Alston, celebrity hairstylist and owner of Sophia Hair, explains, With tape-in hair extensions, there is no commitment; you can change the look from short to long instantly, and this is appealing for people who want an immediate change. These extensions provide many benefits as well. For instance, if you need more fullness, then tape-ins are a fast and easy way to create volume. They are also functional. You can wear your hair up in a ponytail or cascading down around your shoulders. The choice is yours, provided the hair is attached properly and you are doing regular hair-care maintenance, then your look should ultimately last you anywhere from six to eight weeks, says Alston.

Hairstylist and beauty industry executive Dani Tygr says that in addition to choosing the right hair for your desired look, it is also important to remember to choose the right licensed cosmetologist. Its going to all come down to the stylist and their education, not just the application, but consulting with extensions overall. What type of tape-in is the client seeking, and are they the right candidate to wear extensions? These questions must be at the forefront, as choosing the right extensions is the difference between having really bad hair damage and preserving your own hair.

Making the choice to get tape-ins is not completely cut-and-dried, but there is no need to worry; our beauty experts wouldnt dream of leaving you hanging. So we have compiled some of their top choices for your next salon experience. With these suggested brands, youll be showcasing new long and luxurious locks just in time for the summer.

Natural-Looking

Considered global innovators of tape-in extensions, Hair Talk USA has groundbreaking technology and top quality 100 percent Remy human hair. Their patent-pending band style features a completely concealed adhesive band that is made to mimic the natural root and create a nearly invisible result, thus leaving, discreet, comfortable, and flawless natural body wave extensions that blend perfectly with your natural hair.

BELLAMI Professional

With a reputation for quality hair and the largest color shade range, these premium hair extensions are at the forefront of transforming the hair industry. They are made using only the finest cuticle intact, and double-drawn 100 percent Remy human hair.

Glam Seamless is a hair extension brand that provides high-quality hair for every budget. Their hair is made for professional hairstylists and hair extension lovers everywhere. Boasting over 100 colors, multiple lengths, textures, and curl patterns, the company offers hair extension collections from ready-to-wear clip-ins, ponytails, and u-part wigs to professional tape-ins, hand-tied wefts, and more.

Ethically Sourced

Known for its quality, Great Lengths, has 100 percent ethically sourced, traceable virgin human hair from the sacred temples of India, and the most long-lasting, undetectable, and gentle attachment methods.

From ready-to-wear hair to the highest quality of professional hair extensions, The Hair Shop's goal is to provide stylists, beauty enthusiasts, and everyday customers with all the means to transform their mane utilizing a variety of hair textures, versatile lengths, diverse colors, and cutting-edge application methods.

Easy to Apply

These tape-in extensions are quick and easy to apply while lying extremely flat to the scalpa hassle-free option. There are no extra tools required to install this system besides a sectioning comb.

Long-Lasting

Perfect Locks provide a seamless, long-lasting, and manageable solution. They are non-damaging and lightweight, and their Remy human hair can be reused multiple times with hair replacement tape.

Best for Volume

ZALA tape-in human hair extensions pride themselves on using the latest technology in the hair industry. They make it possible to apply a full head of tape-in extensions in under 30 minutes.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Go here to read the rest:

The Top 8 Tape-In Hair Extensions According to Experts - Oprah Mag

Results from pharmacokinetic/pharmacodynamic modeling demonstrated that binding affinity optimization of CS2006/NM21-1480 allowed optimal PD-L1 blockade and 4-1BB stimulation concomitantly, at a broad dose range thereby and facilitating dose-finding in the clinic

CS2006/NM21-1480 was efficacious as monotherapy in both hot and cold tumor models; combination with a CD3-T cell engager resulted in enhanced anti-tumor activity, with increased CD8-positive T memory cells within the tumor

These data provide translational support for the ongoing clinical development of CS2006/NM21-1480 as a potential best-in-class, next-generation immune-oncology agent

SUZHOU, China, April 13, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the preclinical data of multi-specific antibody CS2006/NM21-1480 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Session: PO.IM02.09 - Therapeutic Antibodies 1

Date: April 12, 2022, 9:00 AM - 12:30 PM ET

Format: E-posters

Title: 2870/13-Dose selection investigations and combination strategies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate

Presenter: Dr. Dan Snell

CS2006/NM21-1480 is a monovalent, tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin (HSA). CS2006/NM21-1480 represents a leading class of broadly acting next-generation anti-PD-1/PD-L1 cancer immunotherapies and a new backbone molecule for tumor-specific combination therapies. CS2006/NM21-1480 is designed to bind to the immune co-stimulatory receptor 4-1BB and conditionally activate T cells only when engaging and blocking the checkpoint receptor ligand PD-L1 on the surface of tumor cells, potentially preventing the liver toxicities observed with previous anti-4-1BB agonistic antibodies.

Compared to other PD-L1/4-1BB bispecific antibody candidates, CS2006/NM21-1480's unique monovalent structure and ultra-high-affinity PD-L1-binding are designed to tap the synergistic potential of tumor-localized modulation of PD-L1 and 4-1BB. Furthermore, half-life extension via the HSA-binding is designed to enable convenient dosing schedules for patients. CS2006/NM21-1480 is anticipated to be effective against tumors with a wide range of PD-L1 expression levels and may overcome primary and/or acquired resistance to anti-PD-1/PD-L1 therapies.

Story continues

"The preclinical data of CS2006/NM21-1480 are encouraging and further demonstrate its potential to become a best-in-class anti-4-1BB agonist and next-generation immune checkpoint inhibitor. The bell-shape dose-response curve associated with this class of agents presents a unique challenge with dose-selection in the clinic. However, this concern seems to be alleviated by the fine affinity balance engineered in CS2006/NM21-1480 which allows optimal PD-L1 blockade and 4-1BB activation at the same time." Dr. Archie Tse, Chief Scientific Officer of CStone, said, "The first-in-human dose escalation study is ongoing in the United States, and patient enrollment has commenced in Taiwan, China. In addition, the investigational new drug application has been approved by the National Medical Products Administration of China and the clinical trial is underway. Moving forward, we will step up our efforts to drive research and development of CS2006/NM21-1480, and other pipeline assets to provide high-quality treatments for a wider range of cancer patients as soon as possible."

CS2006/NM21-1480 was discovered and engineered by Numab Therapeutics ("Numab"), CStone's partner, using its proprietary cap technology and MATCH platform. CStone and Numab signed an exclusive regional licensing agreement for the development and commercialization of the drug candidate. Pursuant to the terms of the licensing agreement, CStone will fund the research and development of CS2006/NM21-1480 up to completion of an initial Phase 1b clinical trial. In exchange, CStone obtains exclusive rights from Numab to develop and commercialize CS2006/NM21-1480 in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan), South Korea, and Singapore. Numab retains all CS2006/NM21-1480 rights for the rest of the world. Upon completion of CStone's funding period, no further financial obligations will be owed by either party.

About CStone

CStone (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received seven NDA approvals for four drugs. Multiple late-stage drug candidates are now under pivotal clinical trials or registration. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit http://www.cstonepharma.com.

Forward-looking statement

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

SOURCE CStone Pharmaceuticals

See the article here:

CStone Announces Presentation of Preclinical data on a Multi-Specific Antibody-based Therapeutic Candidate CS2006/NM21-1480 at the American...

The Immigration Services Agency on April 15 agreed to allow people of Myanmar to remain in Japan longer due to the destabilized security situation in their homeland.

The agency has applied to such people preferential treatment as an emergency measure since May 2021 following the coup in Myanmar in February that year.

The agency said it has reviewed the measures because the situation in Myanmar has yet to be improved.

The agency said those who have stayed in Japan around the time of the coup and want to continue to stay but their visa has expired are mainly eligible for the preferential measures.

They have been granted to about 4,600 Myanmar's people by March this year, enabling them to work for six months.

Under the new policy, the period of stay will be lengthened to a year to allow them to have a more secure life in Japan.

The agency also said the number of Myanmar's people who were granted refugee status in 2021 was 32.

The agency apparently concluded that they were subject to persecution if they returned to Myanmar.

The figure was a significant jump from the previous year, when the number was zero.

Go here to read the rest:

Special extension given for people of Myanmar to remain in Japan | The Asahi Shimbun: Breaking News, Japan News and Analysis -

The UN Food and Agriculture Organisations food price index rose 13 per cent last month to stand a third higher than a year ago. Within the index, cereals rose by 17 per cent driven by interrupted Ukrainian and Russian wheat supplies and vegetable oils by 23 per cent, Ukraine being the worlds biggest sunflower farmer. In the UK, wholesale milk is up 20 per cent, as farmers face rising fuel and feed costs. Supermarkets squeeze suppliers to suppress retail prices: but soon, around the same time as our next quarterly gas bills, well feel the full impact at the checkout. And then what?

We may be on the cusp of a new inflationary era, says Agustin Carstens of the Bank for International Settlements: interest rates must rise, however painfully, to fight it. But by how much and to what effect, given that this surge is a crisis of physical supply rather than a monetary phenomenon? And where are the Paul Volckers (of the Fed) or Karl-Otto Phls (of the Bundesbank), those granite-hard currency custodians of old whose mission was price stability above all? I recall Phls words from 1980: Inflation is like toothpaste: once its out of the tube, it is all but impossible to get it back in. But I have no convincing answers to my own questions; and neither, I fear, do todays central bankers.

The death aged 84 of Willy Bauer, dubbed the saviour of the Savoy as its general manager during a celebrated 1980s takeover battle, is a reminder that grand hotels forever calm front-of-house but chaotic in the kitchens provide entertaining corporate dramas. The story then was a decade-long culture clash worthy of the pen of Julian Fellowes: on one side, the up-and-coming Forte dynasty, who acquired majority ownership of the Savoys shares; on the other, an old guard led by the haughty Sir Hugh Wontner, who somehow managed to cling on to voting control.

Todays remake is set in Claridges. Current excitement involves a falling out between the al-Thani family, rulers of Qatar, and the Irish entrepreneur Paddy McKillen the previous owner who the Qataris bought out but retained to run the business when they acquired the parent Maybourne Hotels (which also owns the Berkeley and the Connaught) for 1.3 billion in 2015. Despite record trading at Claridges after a splendid refurbishment, McKillen found himself removed from the board without warning last weekend, says the FT, and is now utterly confused. But hes also entitled to a whopping payout, so watch this space and Im only sorry I cant instantly stream the next episode.

My invitation to last weeks Bitcoin 2022 conference in Miami got lost in the metaverse denying me the chance to heckle the wacko libertarian tech investor Peter Thiel, whose speech attacking leading crypto-sceptics included calling the great stock-picker Warren Buffett a sociopathic grandpa. As for the worlds top banker, Jamie Dimon of JP Morgan Chase, and most prominent institutional investor, Larry Fink of BlackRock, Thiel called them part of a finance geronto-cracy a cohort in which Id be proud to be included, being of an age with both. Thiel himself is so scared of getting old that he reportedly embraces the idea of life extension through blood transfusions from healthy youngsters. I wonder what theyd have to inject to make him talk sense about the delusion of bitcoin.

Id rather have a senior minister whos been successful in business, preferably international business, before entering politics than one who has merely done brilliant brushstrokes of journalism. Im more likely to trust politicians who are competent in managing their personal finances, rather than notorious for not being so. Id like the country to be run by people whose experience has taught them to delegate effectively and deliver complex projects rather than toss out half-baked ideas in the hope that underlings will pick them up or bury them. On the whole I prefer public figures who protect their spouses and stay faithful to them; who tell the truth rather than lie; who look me in the eye and mean what they say. As for how rich they are, if the fortune was honestly made, then I suggest its none of my business or yours.

Any last-minute plans for Easter? Not, I hope, a sunshine getaway involving a flight from Manchester. Or worse, driving an HGV to the continent via Dover in which case, with P&O Ferries suspended, youll likely spend the holiday in a jam on the M20. More irritating still, if you open the back of the truck you may well find nothing in it, because British exporters have become so disheartened by post-Brexit paperwork that up to half of all the lorries bringing imported goods this way across the Channel are currently returning empty.

No, this is a weekend for staying close to home. If youre an entrepreneur, youll be busy filling in the online form for our Economic Innovator of the Year Awards. If youre a futurist, youll be deep in thought as to what kind of venture might sweep the awards a decade hence. We may have leapt forward on decarbonisation by then but I bet well be even more concerned about food security and vegetarian virtue. Our 2032 winner might be a kit to turn your suburban lawn into a model allotment.

Speaking of which, if youre a gastronome, my advice is to get ahead of the game. Forget driving hundreds of 1.80-a-litre miles for a Michelin feast at, lets say, Winteringham Fields in Lincolnshire, recommended by a reader for its 110-per-head eight-course dinner. Instead, stroll to your local, count the money youve saved, and order a big, rare, flame-grilled steak while you still can.

View original post here:

Who can put the toothpaste of inflation back in its tube? - The Spectator

TUESDAY, March 29, 2022 (HealthDay News) -- Despite months of intense lobbying by patient advocates, federal health officials on Monday posted a largely negative review of an experimental drug for the devastating illness known as amyotrophic lateral sclerosis (ALS).

In an analysis of Amylyx Pharmaceuticals' drug, known for now only as AMX3005, regulators from the U.S. Food and Drug Administration said the results were not persuasive. They pointed to missing data, mistakes in enlisting patients and other problems. Meanwhile, the drug only modestly slowed the diseases progression in a 137-patient, mid-stage study. An FDA advisory committee is set to meet Wednesday to consider Amylyx's request to skip the typically required phase 3 clinical trial and approve its drug based on the earlier data.

Several dozen ALS patients and advocates plan to speak at the meeting, and the FDA will weigh the panel's deliberations and vote before making a final ruling on the drug, which is expected by June.

The push to approve the drug follows the agency's controversial approval last year of the Alzheimer's drug Aduhelm. Many of the FDA's own advisors said at the time that the costly drug was unlikely to help patients.

But advocacy groups for patients with ALS are pushing hard for approval of AMX0035. They say the need is urgent.

Most people with ALS, also known as Lou Gehrig's disease, die of respiratory failure within three to five years, according to the U.S. National Institutes of Health. The disease destroys nerve cells needed to walk, talk, swallow and eventually breathe, steadily robbing patients of movement until they're locked inside their own bodies.

Amylyx's request is supported by the ALS Association, one of the main advocacy and research groups devoted to finding a cure for this disease.

"The community has been asking for a long time that the FDA approve the drug before that [phase 3] trial is complete," said Neil Thakur, chief mission officer of the ALS Association. "And the reason why is because of a combination of strong clinical benefit and safety data that we've seen for this this drug."

AMX0035 has been shown in early clinical trials to extend ALS patients' lives by about six and a half months, Thakur said.

The drug also slows disease progression in patients by about 25%, said Dr. James Berry, director of the Massachusetts General Hospital's Neurological Clinical Research Institute in Boston and a principal investigator in the AMX0035 trials.

New drug, new hope

"ALS is a disease that doesn't give us a lot of time to sort of stop and consider," Berry said. "We really need to move when we see something that looks this promising without a safety concern and with a very well-run study that shows us both survival and function benefit."

AMX0035 is a combination of two established drug ingredients -- sodium phenylbutyrate and taurursodiol.

Sodium phenylbutyrate is sold under the brand name Buphenyl to treat liver diseases, while taurursodiol is a dietary supplement used in ancient Chinese medicine. Some ALS patients already take both drugs. FDA approval would likely compel insurers to cover the treatment.

The drugs are known to affect different aspects of ALS, Berry explained.

"The idea was if we took two drugs that sort of fix two different pathways we know are being affected in ALS, they had a chance of having a synergistic effect -- one plus one equals three," Berry said.

Until late last year, the FDA had insisted that Amylyx complete ongoing phase 3 trials before seeking approval for AMX0035.

In December, the agency relented and began a priority review of the drug application, setting June 29 as the target date for a final decision.

Phase 2 trials are typically meant to gather safety data and spot any early signals that would indicate whether a treatment works. Whether a drug actually benefits patients usually isn't established until phase 3 trials. Phase 3 trials involve many more people, so the results are more concrete.

The FDA's decision to fast-track consideration of AMX0035 follows its controversial approval of Aduhelm for Alzheimer's patients.

The agency approved Aduhelm under pressure from advocacy groups and the drug's maker, despite mixed clinical trial results and an advisory panel's recommendation against it.

The advisory panel meeting Wednesday is the same group that recommended against Aduhelm. After the FDA overrode its advice, three members resigned in protest.

Too soon for approval?

Some experts are questioning whether the FDA is repeating history with AMX0035, doing further damage to its scientific credibility by again accepting weaker evidence for a drug touted by disease advocates and drugmakers.

"This is what many people were concerned about in terms of the precedent for FDA approving Aduhelm," Dr. Joseph Ross, a professor of medicine and public health at Yale University, told the Associated Press. "They essentially capitulated to both industry and patient advocacy pressure, as opposed to abiding by the science."

But Thakur, of the ALS Association, argues that the situations are completely different between AMX0035 and Aduhelm.

"Alzheimer's is a slow-acting disease and ALS moves really quickly," he said. "I know people want to compare them because they're all neurology drugs, but the diseases are very different."

In a disease like ALS that takes most lives after a handful of years, six months of extended life is significant, Thakur said.

"What happens if you don't approve the drug and you wait for that phase 3 trial result? You wait a couple of years, and it turns out that the drug works," Thakur said. "Then you would have denied that six and a half months' life extension to all the people who could have been taking the drug. You effectively lose thousands of life years of benefit. And given those two choices, to us, it's a very strong reason to approve the drug as quickly as possible."

The ALS Association invested $2.2 million in Amylyx's research, money raised during the Ice Bucket Challenge campaign that went viral online.

As part of that investment, the ALS Association has what Thakur called a "small royalty stake" that could return up to $3.3 million in proceeds if the drug is approved. He said any money earned from AMX0035 would be plowed back into research.

The ultimate hope is that drug development spurred by Ice Bucket Challenge dollars will lead to medication combinations that extend ALS patients' lives until a cure is found.

"What we're hoping is that drugs like this that have not a life-changing effect but a life-extending effect can work in combination with other drugs, and we can start to transform the experience of ALS to make it a livable disease," Thakur said. "And so a lot of clinical things need to happen, but we also need to transform the treatment space and the drugs that are available, and this could be the start of that process."

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about ALS.

SOURCES: Neil Thakur, PhD, chief mission officer, ALS Association, Arlington, Va.; James Berry, MD, MPH, director, Neurological Clinical Research Institute, Massachusetts General Hospital, Boston; Associated Press

From Your Site Articles

Related Articles Around the Web

Visit link:

FDA Reviewers Give Thumbs Down to New ALS Drug - HealthDay News